Core-binding factors in haematopoiesis and leukaemia

Nature Reviews Cancer

Volumn 2, Issue 7, 2002, Pages 502-513

  Speck, Nancy A ^a   Gilliland, D Gary ^b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; CORE BINDING FACTOR; CYCLIN DEPENDENT KINASE; DNA; DNA BINDING PROTEIN; FLT3 LIGAND; PROTEIN P21; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; STEM CELL FACTOR; TRANSCRIPTION FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CHROMOSOME 21; CHROMOSOME TRANSLOCATION; COLONY FORMING UNIT C; COLONY FORMING UNIT GM; DRUG TARGETING; ERYTHROPOIESIS; FUSION GENE; GENE MUTATION; GENE REARRANGEMENT; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; MYELODYSPLASIA; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DNA BINDING; REVIEW; ANIMAL; CHEMICAL STRUCTURE; DIMERIZATION; ERYTHROCYTE; GENE TRANSLOCATION; GENETICS; LEUKEMIA; METABOLISM; MUTATION; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE;

ANIMALS; DIMERIZATION; ERYTHROCYTES; HEMATOPOIESIS; HUMANS; LEUKEMIA; MODELS, MOLECULAR; MUTATION; PROTEIN STRUCTURE, TERTIARY; TRANSLOCATION, GENETIC;

EID: 0036636857     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc840     Document Type: Article

References (170)

1. Garcia-Porrero, J. A., Godin, I. E. &Dieterlen-Lievre, F.: Potential intraembryonic hemogenic sites at pre-liver stagesin the mouse.Anat. Embryol.192, 425-435 (1995).
2. Tavian, M.: Aorta-associated CD34 hematopoietic cells in the early human embryo.Blood87, 67-72 (1996).
3. Jaffredo, T, Gautier, R., Brajeul, V &Dieterlen-Lievre, F.:Tracing the progeny of the aortic hemangioblast in the avianembryo.Dev. Biol.224, 204-214 (2000).
4. North, T. E.: Runxlexpression marks long-term repopulating hematopoietic stem cells in the midgestationmouse embryo.Immunity 16, 661-672 (2002).
5. Lacoud, G.: Runx1 is essential for hematopoietic commitment at the hemangioblast stage of developmentin vitro.Blood (in the press).
6. Hayashi, K.: Diminution of the AML1 transcription factor function causes differential effects on the fates of CD4 andCD8 single-positive T cells.J. Immunol.165, 6816-6824(2000).
7. Cottles, G. M.: Hematological analysis of AML1-PEBP2aB+/-mice; a possible predisposition tomyeloid leukemia.Blood10, 218 (1999).
8. Ho, C. Y: Linkage of a familial platelet disorder with a propensity to develop myeloid malignancies to humanchromosome.Blood87, 5218-5224 (1996).
9. Song, W.-J.: Haploinsufficiency ofCBFA2 (AML1)causes familial thrombocytopenia with propensity todevelop acute myelogenous leukamia (FPD/AML). NatureGenet.23, 166-175 (1999).
10. Mundlos, S.: Cleidocranial dysplasia: clinical and molecular genetics.J. Med. Genet.36, 177-182 (1999).
11. Miyoshi, H.: Breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited regionof a single gene, AML.Proc. Natl Acad. Sci. USA88, 10431-10434 (1991).
12. Daga, A., Tighe, J. E. &Calabi, F.:Leukaemia/Drosophilahomology.Nature356, 484 (1992).
13. Kagoshima, H.: The Runt domain identifies a new family of heteromeric transcriptional regulators.TrendsGenet.9, 338-341 (1993).
14. Duffy, J. B. &Gergen, J. P.: Sex, segments, and the central nervous system: common genetic mechanisms of cell fatedetermination.Adv. Genet.31, 1-28 (1994).
15. Kamachi, Y.: Purification of a mouse nuclear factor that binds to both the A and B cores of the polyomavirusenhancer.J. Virol.64, 4808-4819 (1990).
16. Wang, S. &Speck, N. A.: Purification of core-binding factor, a protein that binds the conserved core site in murine leukemiavirus enhancers.Mol. Cell. Biol.12, 89-102 (1992).
17. Ogawa, E.: Molecular cloning and characterization of PEBP2p, the heterodimeric partner of a novelDrosophilaRunt-related DNA binding protein PEBP2a.Virology194, 314-331 (1993).
18. Ogawa, E.: PEBP2/PEA2 represents a new family of transcription factor homologous to the products of theDrosophilaruntand the humanAML1gene.Proc. NatlAcad. Sci. USA90, 6859-6863 (1993).
19. Wang, S.: Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancercore-binding factor.Mol. Cell. Biol.13, 3324-3339 (1993).
20. Liu, P.:Fusion between transcription factorCBFp/PEBP2p and a myosin heavy chain in acute myeloidleukemia.Science261, 1041-1044 (1993).
21. Huang, G.: Dimerization with PEBP2p protects RUNX1/AML1 from ubiquitin-proteosome-mediateddegradation.EMBO J.15, 723-733 (2001).
22. Li, L. H. &Gergen, J. P.: Differential interactions between Brother proteins and Runt domain proteins in theDrosophilaembryo and eye.Development126, 3313-3322 (1999).
23. Sakuma, T.: Cloning and expression pattern of a novelPEBP2p-binding protein (charged amino acid rich leucinezipper-1[Crl-1]) in the mouse.Mech. Dev.104, 151-154(2001).
24. Okuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G. &Downing, J. R.:AML1, the target of multiple chromosomaltranslocations in human leukemia, is essential for normalfetal liver hematopoiesis.Cell84, 321-330 (1996).
25. Wang, Q.: Disruption of theCbfa2gene causes necrosis and hemorrhaging in the central nervous systemand blocks definitive hematopoiesis.Proc. Natl Acad. Sci.USA93, 3444-3449 (1996).
26. Wang, Q.: The CBFp subunit is essential for CBFa2 (AML1) functionin vivo. Cell87, 697-708 (1996).
27. Sasaki, K.: Absence of fetal liver hematopoiesis in transcriptional co-activator, core binding factor p(Cbfb)deficient mice.Proc. Natl Acad. Sci. USA93, 12359-12363 (1996).
28. Giese, K., Kingsley, C., Kirshner, J. R. &Grosschedl, R.: Assembly and function of a TCRa enhancer complex isdependent on LEF-1-induced DNA binding and multipleprotein-protein interactions.Genes Dev.9, 995-1008 (1995).
29. Uchida, H., Zhang, J. &Nimer, S. D.: AML1A and AML1B can transactivate the human IL-3 promoter.J. Immunol. 158, 2251-2258 (1997).
30. Wargnier, A.: Identification of human granzyme B promoter regulatory elements interacting with activatedT-cell-specific proteins: implication of Ikaros and CBFbinding sites in promoter activation.Proc. Natl Acad. Sci.USA92, 6930-6934 (1995).
31. Taka has hi, A.: Positive and negative regulation of granulocyte-macrophage colony-stimulating factor (GM-CSF) promoter activity by AML1-related transcription factor, PEBP2.Blood86, 607-616 (1995).
32. Brown, S. T: Regulation of theRAG1promoter by the NF-Y transcription factor.J. Immunol.158, 5071-5074 (1997).
33. Armesilla, A. L., Calvo, D. &Vega, M. A.: Structural andfunctional characterization of the human CD36 genepromoter: identification of a proximal PEBP2/CBF site. J. Biol. Chem.27, 7781-7787 (1996).
34. Lutterbach, B.: A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomaltranslocations in acute leukemia.J. Biol. Chem.275, 651-656 (2000).
35. Palis, J., Robertson, S., Kennedy, M., Wall, C. &Keller, G.: Development of erythroid and myeloid progenitors in theyolk sac and embryo proper of the mouse.Development126, 5073-5084 (1999).
36. Godin, I., Dieterlen-Lievre, F. &Cumano, A.: Emergence of multipotent hematopoietic cells in the yolk sac andparaaortic splanchnopleura of 8.5 dpc mouse embryos.Proc. Natl Acad. Sci. USA92, 773-777 (1995).
37. De Bruijn, M. F. T. R., Speck, N. A., Peeters, M. C. E. & Dzierzak, E.: Definitive hematopoietic stem cells first emergefrom the major arterial regions of the mouse embryo. EMBO J.19, 2465-2474 (2000).
38. Niki, M.: Hematopoiesis in the fetal liver is impaired by targeted mutagenesis of a gene encoding a non-DNAbinding subunit of the transcription factor, polyomavirusenhancer binding protein 2/core binding factor.Proc. NatlAcad. Sci. USA94, 5697-5702 (1997).
39. Cai, Z.: Haploinsufficiency ofAML1/CBFA2affects the embryonic generation of mouse hematopoietic stem cells.Immunity 13, 423-431 (2000).
40. Castilla, L. H.:Defects of embryonic hematopoiesis and lethal hemorrhaging in mouse embryos heterozygous for aknocked-in leukemia geneCBFB-MYH11. Cell 87, 687-696 (1996).
41. Yokomizo, T: RUNX1/AML1/PEBP2aBis involved in primitive hematopoiesis in addition to definitivehematopoiesis.Blood 96, 283 (2000).
42. North, T. E.: Cbfa2is required for the formation of intraaortic hematopoietic clusters.Development126, 2563-2575 (1999).
43. Mukouyama, Y: The AML1 transcription factor functions to develop and maintain hematogenic precursorcells in the embryonic aorta-gonad-mesonephros region.Dev. Biol.220, 27-36 (2000).
44. Yokomizo, T: Requirement of Runx1-AML1-PEBP2aB for the generation of haematopoietic cells from endothelialcells.Genes Cells 6, 13-23 (2001).
45. Michaud, J.: In vitroanalyses of known and novelRUNX1-AML1mutations in dominant familial plateletdisorder with predisposition to acute myelogenousleukemia: implications for mechanisms of pathogenesis.Blood 99, 1364-1372 (2002).
46. Osato, M.: Biallelic and heterozygous point mutations in the Runt domain of theAML1-PEBP2aBgeneassociated with myeloblastic leukemias.Blood 93, 1817-1824 (1999).
47. Preudhomme, C.: High incidence of biallelic point mutations in the Runt domain of theAML1/PEBP2aBgenein M0acute myeloid leukemia and in myeloid malignancieswith acquired trisomy 21.Blood96, 2862-2869 (2000).
48. Dal Cin, P: Amplification of AML1 in childhood acute lymphoblastic leukemias.Genes Chromosom. Cancer 30, 407-409 (2001).
49. Hilgenfeld, E.: Spectral karyotyping and fluorescencein situhybridization detect novel chromosomal aberrations, arecurring involvement of chromosome 21 and amplificationof the MYC oncogene in acute myeloid leukaemia M2. Br. J. Haematol.113, 305-317 (2001).
50. Mathew, S., Rao, P. H., Dalton, J., Downing, J. R. &Raimondi, S. C.: Multicolor spectral karyotyping identifiesnovel translocations in childhood acute lymphoblasticleukemia.Leukemia15, 468-472 (2001).
51. Niini, T, Kanerva, J., Vettenranta, K., Saarinen-Pihkala, U. M. &Knuutila, S.:AML1gene amplification: a novel finding inchildhood acute lymphoblastic leukemia.Haematologica85, 362-366 (2000).
52. Streubel, B., Valent, P., Lechner, K. &Fonatsch, C.: Amplification of theAML1(CBFA2) gene on ringchromosomes in a patient with acute myeloid leukemia anda constitutional ring chromosome 21.Cancer Genet.Cytogenet.124, 42-46 (2001).
53. Stewart, M.: Proviral insertions induce the expression of bone-specific isoforms ofPEBP2aA (CBFA1):evidence for anew myc collaborating oncogene.Proc. Natl Acad. Sci. USA94, 8646-8651 (1997).
54. Blyth, K.: Sensitivity to Myc-induced apoptosis is retained in spontaneous and transplanted lymphomas ofCD2-mycER mice.Oncogene19, 773-782 (2000).
55. Blyth, K.: Runx: a novel oncogenic effector revealed byIn vivocomplementation and retroviral tagging. Oncogene20, 295-302 (2001).
56. Li, J.: Leukaemia disease genes: large-scale cloning and pathway predictions.Nature Genet.23, 348-353(1999).
57. Downing, J. R.: AnAML1-ETOfusion transcript is consistently detected by RNA-based polymerase chainreaction in acute myelogenous leukemia containing the(8;21)(q22;q22) translocation.Blood81, 2860-2865 (1993).
58. Erickson, P: Identification of breakpoints in t(8;21) AMLand isolation of a fusion transcript with similarity toDrosophilasegmentation generunt. Blood80, 1825-1831(1992).
59. Meyers, S., Downing, J. R. &Hiebert, S. W.: Identification of AML1 and the (8;21) translocation protein (AML1-ETO) assequence-specific DNA-binding proteins: the Runthomology domain is required for DNA binding and protein-protein interactions.Mol. Cell. Biol.13, 6336-6345 (1993).
60. Nucifora, G.: Detection of DNA rearrangement in theAMLandETOloci and of anAML1-ETOfusion mRNA inpatients with.Blood81, 883 (1993).
61. Golub, T. R.: Fusion of theTELgene on 12p13 to theAML1gene on 21q22 in acute lymphoblastic leukemia. Proc. Natl Acad. Sci. USA92, 4917-4921 (1995).
62. Romana, S. P: The t(12;21) of acute lymphoblastic leukemia results in aTEL-AML1gene fusion.Blood85, 3662-3670 (1995).
63. McLean, T. W.: TEL-AML1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblasticleukemia.Blood88, 4252-4258 (1996).
64. Romana, S. P: High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia.Blood86, 4263-4269 (1995).
65. Liang, D. C.: High incidence of TEL-AML1 fusion resulting from a cryptic t(12;21) in childhood B-lineage acutelymphoblastic leukemia in Taiwan.Leukemia10, 991-993(1996).
66. Mitani, K.: Generation of theAML1-EVI1fusion gene in the t(3, 21)(q26;q22) causes blastic crisis in chronicmyelocytic leukemia.EMBO J.13, 504-510 (1994).
67. Nucifora, G.: Consistent intergenic splicing and production of multiple transcripts betweenAML1at 21q22and unrelated genes at 3q26 in (3;21)(q26;q22)translocations.Proc. Natl Acad. Sci. USA91, 4004-4008(1994).
68. Meyers, S., Lenny, N. &Hiebert, S. W.: The t(8;21) fusion protein interferes with AML1 -1B-dependent transcriptionalactivation.Mol. Cell. Biol.15, 1974-1982 (1995).
69. Hiebert, S. W.: The t(12;21) translocation converts AML1B from an activator to a repressor of transcription. Mol. Cell. Biol.16, 1349-1355 (1996).
70. Lutterbach, B., Hou, Y., Durst, K. L. &Hiebert, S. W.: The inv(16) encodes an acute myeloid leukemia 1 transcriptionalcorepressor.Proc. Natl Acad. Sci. USA96, 12822-12827(1999).
71. Yergeau, D. A.:Embryonic lethality and impairment of hematopoiesis in mice heterozygous for anAML1-ETOfusion gene.Nature Genet.15, 303-306 (1997).
72. Okuda, T: Expression of a knocked-inAML1-ETOleukemia gene inhibits the establishment of normal definitivehematopoiesis and directly generates dysplastichematopoietic progenitors.Blood91, 3134-3143 (1998).
73. Okuda, T: These two reports show that the RUNX1-ETO fusionhas dominant-negative activity for the native RUNX1during development.
74. Shimizu, K.: AML1-MTG8 leukemic protein induces the expression of granulocyte colony-stimulating factor (G-CSF)receptor through the up-regulation of CCAAT/enhancerbinding protein epsilon.Blood 96, 288-296 (2000).
75. Rhoades, K. L.: Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusionprotein may contribute to leukemogenesis.Procl Natl AcadlSci. USA93, 11895-11900 (1996).
76. Mulloy, J. C.: The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells.Blood99, 15-23 (2002).
77. Lutterbach, B.: ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3corepressors.Mol. Cell. Biol.18, 7176-7184 (1998).
78. Gelmetti, V.: Aberrant recruitment of the nuclearreceptor corepressor-histone deacetylase complex by theacute myeloid leukemia fusion partner ETO.Mol. Cell. Biol.18, 7185-7191 (1998).
79. Fenrick, R.: Both TEL and AML1 contribute repression domains to the t(12;21) fusion protein.Mol. Cell. Biol.19, 6566-6574 (1999).
80. Adja, N., Stacy, T., Speck, N. A. &Liu, P P.: The leukemic protein CBFp-SMMHC sequesters CBFa2 into cytoskeletalfilaments and aggregates.Moll Celll Bioll18, 7432-7443 (1998).
81. Kanno, Y., Kanno, T, Sakakura, C., Bae, S.-C. &Ito, Y.: Cytoplasmic sequestration of the polyomavirus enhancerbinding protein 2 (PEBP2)/core binding factor a (CBFa)subunit by the leukemia-related PEBP2-CBFp-SMMHCfusion protein inhibits PEBP2/CBF-mediated transactivation.Mol. Cell. Biol.18, 4252-4261 (1998).
82. Chen, Z.: PLZF-RARa fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acutepromyelocytic leukemia inhibit ligand-dependenttransactivation of wild-type retinoic acid receptors. Proc. Natl Acad. Sci. USA91, 1178-1182 (1994).
83. Melnick, A. &Licht, J. D.: Deconstructing a disease: RARa, its fusion partners, and their roles in the pathogenesis ofacute promyelocytic leukemia.Blood 93, 3167-3215 (1999).
84. Melnick, A.: AML1-ETO fusion protein is a dominant negative inhibitor of transcriptional repression by thepromyelocytic leukemia zinc finger protein.Blood 96, 3939-3947 (2000).
85. Melnick, A. M.: The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein.Moll Celll Bioll20, 2075-2086 (2000).
86. Minucci, S.: Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenicactivation.Moll Cell5, 811-820 (2000).
87. Lin, R. J. &Evans, R. M.: Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia throughformation of homodimers.Mol. Cell5, 821-830 (2000).
88. Zhang, J.: Oligomerization of ETO is obligatory forcorepressor interaction.Mol. Cell Biol.21, 156-163 (2001).
89. Wang, J., Saunthararajah, Y., Redner, R. L. &Liu, J. M.:Inhibitors of histone deacetylase relieve ETO-mediatedrepression and induce differentiation of AML1 -ETO leukemiacells.Cancer Res.59, 2766-2769 (1999).
90. Westendorf, J. J.: The t(8;21) fusion product, AML1-ETO, associates with C/EBPa, inhibits C/EBPa-dependent transcription, and blocks granulocyticdifferentiation.Mol. Cell. Biol.18, 322-333 (1998).
91. Wiemels, J. L.: Prenatal origin of acute lymphoblastic leukaemia in children.Lancet354, 1499-1503 (1999).
92. Wiemels, J. L.: Elegant demonstration, using Guthrie cards, of theprenatal origin of TEL-RUNX1 leukaemia in paediatricALL, The multistep pathogenesis of ALL.
93. Wiemels, J. L., Ford, A. M., van Wering, E. R., Postma, A. &Greaves, M.: Protracted and variable latency of acutelymphoblastic leukemia afterTEL-AML1gene fusioninutero. Blood 94, 1057-1062 (1999).
94. Ford, A. M.: Fetal origins of theTEL-AML1fusion gene in identical twins with leukemia.Proc. Natl Acad. Sci. USA95, 4584-4588 (1998).
95. Downing, J. R.: AML1 -CBFp transcription complex: its role in normal hematopoiesis and leukemia.Leukemia15, 664-665 (2001).
96. Higuchi, M.: Expression of a conditionalAML1-ETOoncogene bypasses embryonic lethality and establishes amurine model of human t(8;21) acute myeloid leukemia.Cancer Cell1, 63-74 (2002).
97. Castilla, L. H.: Chromosome 16 inversion-generated fusion geneCbfb-MYH11blocks myeloid differentiation andpredisposes mice to acute myelomonocytic leukemia.Nature Genet.23, 144-146 (1999).
98. Kundu, M. &Liu, P. P.: Function of the inv(16) fusion geneCBFB-MYH11. Curr. Opin. Hematol.8, 201-205 (2001).
99. Gilliland, G., Patterson, E. J., Rosenthal, D. S. &Tantravahi, R.:Multiple clones with (3;21) translocation in a case of Ph-positive chronic myelogenous leukemia during relapse afterallogeneic bone marrow transplantation. Cancer GenetlCytogenet.47, 55-60 (1990).
100. Melo, J. V.: The molecular biology of chronic myeloid leukaemia.Leukemia10, 751-756 (1996).
101. Kojima, K.: Additional translocation (8;21)(q22;q22) in a patient with Philadelphia-positive chronic myelogenousleukaemia in the blastic phase.Brl Jl Haematoll106, 720-722 (1999).
102. Golub, T. R., Barker, G. F., Lovett, M. &Gilliland, D. G.: Fusion of PDGF receptor-p to a novel ETS-like gene, TEL, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.Cell77, 307-316 (1994).
103. Daley, G. Q., Van Etten, R. A. &Baltimore, D.: Induction of chronic myelogenous leukemia in mice by theP210BCR-ABLgene of the Philadelphia chromosome.Science247, 824-830 (1990).
104. Tomasson, M. H.: Fatal myeloproliferation, induced in mice byTel-Pdgfprexpression, depends on Pdgfprtyrosines 579/581.J. Clin. Invest.105, 423-432 (2000).
105. Nakao, M.: Internal tandem duplication of theFLT3gene found in acute myeloid leukemia.Leukemia10, 1911-1918 (1996).
106. Rombouts, W., Blokland, I., Lowenberg, B. &Ploemacher, R.: Biological characteristics and prognosis of adult acutemyeloid leukemia with internal tandem duplications in theFLT3gene.Leukemia14, 675-683 (2000).
107. Kottaridis, P D.: The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia(AML) adds important prognostic information to cytogeneticrisk group and response to the first cycle of chemotherapy:analysis of 854 patients from the United Kingdom MedicalResearch Council AML 10 and 12 trials. Blood 98, 1752-1759 (2001).
108. Radich, J. P.: N-RASmutations in adultde novoacute myelogenous leukemia: prevalence and clinical significance.Blood76, 801-807 (1990).
109. Neubauer, A.: Prognostic importance of mutations in therasproto-oncogenes inde novoacute myeloidleukemia.Blood83, 1603-1611 (1994).
110. Kubo, K.: Clonal analysis of multiple point mutations in the N-rasgene in patients with acute myeloid leukemia.JpnlJ. Cancer Res.84, 379-387 (1993).
111. Byrd, J. C.: Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overallsurvival when repetitive cycles of high-dose cytarabine areadministered.J. Clin. Oncol.17, 3767-3775 (1999).
112. Marcucci, G., Caligiuri, M. A. &Bloomfield, C. D.: Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm fortranslational research in malignant hematology.CancerInvestl18, 768-780 (2000).
113. Mrozek, K., Heinonen, K. &Bloomfield, C. D.: Prognostic value of cytogenetic findings in adults with acute myeloidleukemia.Int. J. Hematol.72, 261-271 (2000).
114. Mrozek, K., Heinonen, K. &Bloomfield, C. D.: Clinical importance of cytogenetics in acute myeloid leukaemia. Best Pract. Res. Clin. Haematol.14, 19-47 (2001).
115. Shurtleff, S. A.: TEL-AMLfusion resulting from a cryptic t(12;21) is the most common genetic lesion inpediatric ALL and defines a subgroup of patients with anexcellent prognosis.Leukemia9, 1985-1989 (1995).
116. Rubnitz, J. E.: TELgene rearrangement in acutelymphoblastic leukemia: a new genetic marker withprognostic significance.J. Clin. Oncol.15, 1150-1157(1997).
117. Rubnitz, J. E.: Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineageacute lymphoblastic leukemia treated with antimetabolite-based therapy: a Pediatric Oncology Group study.Blood 89, 1143-1146 (1997).
118. Rubnitz, J. E., Downing, J. R. &Pui, C. H.: Significance of theTEL-AMLfusion gene in childhood AML.Leukemia13, 1470-1471 (1999).
119. Loh, M. L.: Incidence ofTEL-AML1fusion in children with relapsed acute lymphoblastic leukemia.Blood 92, 4792-4797 (1998).
120. Borkhardt, A.: Incidence and clinical relevance ofTEL-AML1fusion genes in children with acutelymphoblastic leukemia enrolled in the German and Italianmulticenter therapy trials. Associazione Italiana EmatologiaOncologia Pediatrica and the Berlin-Frankfurt-MunsterStudy Group.Blood90, 571-577 (1997).
121. Borkhardt, A., Harbott, J. &Lampert, F.: Biology and clinical significance of theTEL-AML1rearrangement.Curr. Opin.Pediatr.11, 33-38 (1999).
122. Harbott, J., Viehmann, S., Borkhardt, A., Henze, G. &Lampert, F.: Incidence ofTEL-AMLfusion gene analyzedconsecutively in children with acute lymphoblastic leukemiain relapse.Blood90, 4933 (1997).
123. Druker, B. J.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronicmyeloid leukemia and acute lymphoblastic leukemia with thePhiladelphia chromosome.Nl Engll Jl Medl344, 1038-1042 (2001).
124. Muller, A. M., Medvinsky, A., Strouboulis, J., Grosveld, F. &Dzierzak, E.: Development of hematopoietic stem cell activityin the mouse embryo.Immunity1, 291-301 (1994).
125. Medvinsky, A. &Dzierzak, E.: Definitive hematopoiesis isautonomously initiated by the AGM region.Cell86, 897-906(1996).
126. Choi, K., Kennedy, M., Kazarov, A., Papadimitriou, J. C. &Keller, G.: A common precursor for hematopoietic andendothelial cells.Development125, 725-732 (1998).
127. Nishikawa, S.-I.: In vitrogeneration oflymphohematopoietic cells from endothelial cells purifiedfrom murine embryos.Immunity8, 761-769 (1998).
128. Jaffredo, T, Gautier, R., Eichmann, A. &Dieterlen-Lievre, F.: Intraaortic hemopoietic cells are derived from endothelialcells during ontogeny.Development125, 4575-4583 (1998).
129. Kanno, T.: Intrinsic transcriptional activation-inhibition domains of the polyomavirus enhancer binding protein2/core binding factor-a subunit revealed in the presence ofthe |3-subunit.Mol. Cell. Biol.18, 2444-2454 (1998).
130. Gu, T.-L., Goetz, T L., Graves, B. J. &Speck, N. A.: Autoinhibition and partner proteins, CBFp and Ets-1, modulate DNA binding by CBFa2 (AML1).Mol, Cell, Biol, 20, 91-103 (2000).
131. Zeng, C.: Identification of a nuclear matrix targeting signal in the leukemia and bone-related AML/CBF-atranscription factors.Proc, NatlAcad, Sci, USA94, 6746-6751 (1997).
132. Zeng, C.: Intranuclear targeting of AML/CBFa regulatory factors to nuclear matrix-associatedtranscriptional domains.Proc, Natl Acad, Sci, USA95, 1585-1589 (1998).
133. Ahn, M.-Y.: Negative regulation of granulocytic differentiation in the myeloid precursor cell Line 32Dc13 byear-2, a mammalian homolog ofDrosophila seven-up, and achimeric leukemogenic gene, AML1-ETO(MTG8). Proc, NatlAcad, Sci, USA95, 1812-1817 (1998).
134. Bruhn, L., Munnerlyn, A. &Grosschedl, R.: ALY, a context-dependent coactivator of LEF1 and AML1, is required for TCRa enhancer function.Genes Devl11, 640-653 (1997).
135. Petrovick, M. S.: Multiple functional domains of AML1: PU. 1 and C/EBPasynergize with different regions of AML.MoI, Ceil. Biol.18, 3915-3925 (1998).
136. Yagi, R., Chen, L.-F., Shigesda, K., Murakami, Y &Ito, Y. A.: WW domain-containing Yes-associated protein (YAP) is anovel transcriptional co-activatorEMBO J, 18, 2551-2562 (1999).
137. Zhang, D.-E.: CCAAT enhancer-binding protein (C/EBP) and AML1 (CBFa2) synergistically activate themacrophage colony-stimulating factor receptor promoter.Mol, Cell, Biol, 16, 1231-1240 (1996).
138. Libermann, T. A.: AML1 (CBFa2) cooperates with B cell-specific activating protein (BSAP/PAX5) in activation ofthe B cell-specific BLK gene promoter.J, Biol, Chem, 274, 24671-24676 (1999).
139. Mao, S., Frank, R. C., Zhang, J., Miyazaki, Y. &Nimer, S. D.: Functional and physical interactions between AML1 proteinsand an ETS protein, MEF: implications for the pathogenesisof t(8;21)-positive leukemias.Mol, Cell, Biol, 19, 3635-3644(1999).
140. Kitabayashi, I., Yokoyama, A., Shimizu, K. &Ohki, M.: Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid celldifferentiation.EMBO J, 17, 2294-3004 (1998).
141. Levanon, D.: Transcriptional repression by AML1 and LEF-1 is mediated by the TLE/Groucho corepressors.ProclNatl Acad, Sci, USA95, 11590-11595 (1998).
142. Aronson, B. D., Fisher, A. L., Blechman, K., Caudy, M. &Gergen, J. P.: Groucho-dependent and -independentrepression activities of Runt domain proteins.Mol, Cell, Biol, 17, 581-587 (1997).
143. Chen, L.-F., Ito, K., Murakami, Y &Ito, Y.: The capacity of polyomavirus enhancer binding protein 2aB (AML1/Cbfa2)to stimulate polyomavirus DNA replication is related to itsaffinity for the nuclear matrix.Mol, Cell, Biol, 18, 4165-4176 (1998).
144. Miller, J. D., Stacy, T, Liu, P. P &Speck, N. A.: CBFp, but not CBFp-SMMHC rescues definitive hematopoiesis in CBFp-deficient embryonic stem cells.Blood97, 2248-2256(2001).
145. Tang, Y.-Y.: Energetic and functional contribution of residues in the core binding factor-p (CBFp) subunit toheterodimerization with CBFa.Jl Bioll Cheml275, 39579-39588 (2000).
146. Nagata, T.: Immunoglobulin motif DNA-binding and heterodimerization for the PEBP2/CBF Runt-domain. Nature Struct, Biol, 6, 615-619 (1999).
147. Berardi, M.: The Ig fold of the core binding factor a Runt domain is a member of a family of structurally andfunctionally related Ig fold DNA binding domains.StructureFold Des, 7, 1247-1256 (1999).
148. Tahirov, T H.: Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control byCBFp.Cell104, 755-767 (2001).
149. Bravo, J., Li, Z., Speck, N. A. & Warren, A. J.: The leukaemia-associated AML1 (Runx1)-CBFp complexfunctions as a DNA-induced molecular clamp.NatureStructl Bioll8, 371-377 (2001).
150. Bravo, J., Li, Z., Speck, N. A. &Warren, A. J.: These two reports provide elegant structural characterization of RUNX1 complexed with itsheterodimeric partner CBFpand DNA, indicating abasis for the allosteric control of RUNX1 by CBFpand DNA.
151. Rudolph, M. J. &Gergen, J. P. DNA-binding by Ig-fold proteins.Nature Struct, Biol, 8, 384-386 (2001).
152. Huang, X., Peng, J. W., Speck, N. A. &Bushweller, J. H.: Solution structure of core binding factor-p and map of theCBFa binding site.Nature Struct, Biol, 6, 624-627 (1999).
153. Goger, M.: Molecular insights into PEBP2-CBFp-SMMHC associated acute leukemia revealed from thethree-dimensional structure of PEBP2-CBFp.Nature StructlBiol, 6, 620-623 (1999).
154. Tang, Y.-Y.: Biophysical characterization of interactions between the core-binding factor-a and -p subunits andDNA.FEBS Lett, 470, 167-172 (2000).
155. Langabeer, S. E., Gale, R. E., Rollinson, S. J., Morgan, G. J. &Linch, D. C.: Mutations of theAML1gene in acute myeloidleukemia of the FAB types M0 and M7.Genes ChromosomlCancer34, 24-32 (2002).
156. Imai, Y.:Mutations of theAML1gene in myelodysplastic syndrome and their functional implicationsin leukemogenesis.Blood 96, 3154-3160 (2000).
157. Buijs, A.: A novelCBFA2single-nucleotide mutation in familial platelet disorder with propensity to develop myeloidmalignancies.Blood 98, 2856-2858 (2001).
158. Lanza, C.: The commonTEL-AML1rearrangement does not represent a frequent event in acute lymphoblasticleukaemia occuring in children with Down syndrome.Leukemia11, 820-821 (1997).
159. Takahashi, Y.: Prognostic significance ofTEL-AML1fusion transcript in childhood B-precursor acutelymphoblastic leukemia.J, Pediatr, Hematol, Oncol, 20, 190-195 (1998).
160. Ayigad, S.: TEL-AML1fusion transcript designates a favorable outcome with an intensified protocol in childhoodacute lymphoblastic leukemia.Leukemia13, 481-483(1999).
161. Maloney, K.: TEL-AML1 fusion identifies a subset of children with standard risk acute lymphoblastic leukemiawho have an excellent prognosis when treated with therapythat includes single delayed intensification.Leukemia 13, 1708-1712 (1999).
162. Hann, I.: Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results fromMedical Research Council United Kingdom acutelymphoblastic leukaemia XI protocol.Brl Jl Haematoll113, 103-114 (2001).
163. Hubeek, I.: TEL-AML1 fusion is not a prognostic factor in Dutch childhood acute lymphoblastic leukaemia.Brl JlHaematol, 113, 254-255 (2001).
164. Tsang, K. S.: TEL-AML1rearrangement and the prognostic significance in childhood acute lymphoblasticleukemia in Hong Kong.Am, J, Hematol, 68, 91-98(2001).
165. Uckun, F. M.: Expression ofTEL-AML1fusion transcripts and response to induction therapy in standardrisk acute lymphoblastic leukemia.Leukl Lymphl42, 41-56(2001).
166. Seeger, K.: TEL-AML1fusion transcript in relapsed childhood acute lymphoblastic leukemia.Blood 91, 1716-1722 (1998).
167. Loh, M. L.: Incidence ofTEL-AML1fusion in children with relapsed acute lymphoblastic leukemia.Blood 92, 4792-4797 (1998).
168. Rubnitz, J. E.: Low frequency ofTEL-AML1in relapsed acute lymphoblastic leukemia supports a favorableprognosis for this genetic subgroup.Leukemia 13, 19-21(1999).
169. Zuna, J.: Significantly lower relapse rate for TEL-AML1-positive ALL.Leukemia13, 1633(1999).
170. Tracey, D. W. &Speck, N. A.: Potential roles for RUNX1 and its orthologues in determining hematopoietic cell fate.SemlCell Devl Biol.11, 337-342 (2000).